Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Aprea Therapeutics, Inc. (APRE)

Aprea Therapeutics Expands Patent Portfolio With 28 Issued and 30 Pending Patents

Neutral Impact 2 of 5 product/contract Written later

Aprea Therapeutics announced an update to its intellectual property portfolio covering its precision oncology programs, citing 28 issued and 30 pending patents. The filing reports no financial results, and it does not describe any change in the company's clinical programs or financial position.

Key points

  • Company reports 28 issued and 30 pending patents across its programs.
  • WEE1 family of applications, if granted, would expire in 2047, excluding any regulatory exclusivities.
  • ATR inhibitor granted patents expire 2035-2037; pending applications could extend exclusivity into 2045.
  • Company is considering further development of ATRN-119 in combination therapies after completing dose escalation.

The filing

CompanyAprea Therapeutics, Inc. (APRE)
Form8-K, current report
Filed with the SECAug 28, 2026, 8:30 AM ET
Accession number0001104659-26-102795

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.